Anti-Inflammatory drug may ease swallowing in rare skin disease

NCT ID NCT07684105

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study investigates whether budesonide, an anti-inflammatory medication, can improve swallowing difficulties in people with dystrophic epidermolysis bullosa, a rare genetic condition that causes fragile skin and scarring. The researchers will review medical records of 15 patients who took budesonide for at least one month. The goal is to see if the treatment reduces the need for esophageal dilation and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
budesonide (Jorveza)
What this could lead to
If successful, this could point toward a treatment to ease swallowing problems in people with dystrophic epidermolysis bullosa.
What could go wrong
This is a small, retrospective study with only 15 participants, so results may not apply to everyone. The treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSPHAGIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHP Necker

    Paris, France, 75000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • APHP St Louis

    Paris, France, 75000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Nice

    Nice, France, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.